Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s dermatologicals

Executive Summary

The Indian drugmaker plans to launch three branded dermatological products in the U.S. by the end of 2009 through its newly-established Bridgewater, N.J.-based Promius Pharma subsidiary. The products, which were in-licensed and co-developed, include: EpiCeram skin barrier emulsion for atopic dermatitis, Scytera foam for psoriasis and Promiseb cream for seborrheic dermatitis. Other topical products are in development. Dr. Reddy's established Promius as a platform for its U.S. branded specialty drug business (1PharmAsia News, Aug. 19, 2008)

You may also be interested in...



New Face For Dr Reddy’s Dermatology Business

MUMBAI - In what could be a significant push to its dermatology business in the U.S., Dr Reddy's Labs has carved out a new company - Promius Pharma to establish a distinct identity for its branded specialty products

Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry

In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.

TytoCare Raised $50m In Funding Amid Rising Demand To Remotely Monitor COVID-19 Patients

TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.

UsernamePublicRestriction

Register

PS050116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel